Think360.ai has been honored as one of the top providers in AIM Research’s GenAI PeMa Quadrant 2024, underscoring the company’s leadership and innovation in the Generative AI (GenAI) space. With global GenAI adoption driving an estimated $1.3 billion in projected … Read More
global
Think360.ai Named Top Data Science Service Provider in AIM Research’s PeMA Quadrant 2024
The recognition of Think360.ai as one of the top data science service providers in AIM Research’s PeMA Quadrant 2024 is a testament to the company’s excellence and leadership in the field. With global data science adoption projected to grow at … Read More
Fixed vs. Variable Commercial Cost Models in the Pharma Commercial Operations
The pharmaceutical and life sciences industry has witnessed significant shifts in market dynamics, scientific advancements, and the impact of the COVID-19 pandemic. Consequently, the discussion around fixed versus variable commercial launch models has become increasingly pertinent. This blog explores the … Read More
Building Internal Expertise vs. Using External Partner for Commercial Operations
The pharmaceutical industry is at a crossroads when it comes to managing drug lifecycles, from launch to maturity. A pivotal decision lies in choosing between building internal expertise and leveraging external partner expertise. This strategic choice significantly impacts an organization’s … Read More
Customer Centricity: The path to success in a dynamic world
In today’s fast-paced and competitive business world, the shift from product-centric to customer-centric approaches has become a defining factor for an organization’s success. Understanding what customer centricity means and embracing it as a strategic imperative can significantly impact an organization’s … Read More
Identifying high potential early-stage investment opportunities in the pharmaceutical industry
Background The biotechnology and pharmaceutical industries are facing significant challenges with their existing business models due to expiring drug patents, also known as patent cliff. Patents on drugs are typically for twenty years from the patent approval until expiration, although … Read More
Prioritizing healthcare professionals targeting in the post COVID-19 world
Given the changes in market due to coronavirus pandemic, pharmaceutical companies are advised to refine their commercial models—keeping in mind the needs of patients and healthcare professionals The coronavirus pandemic has given a new definition to normal by creating an … Read More
Managing medical debt & reimagining patient experience during COVID-19
The COVID-19 pandemic has resulted in a “mini pandemic” in the form of medical debt and patient stress. We need to be “smart” about managing it The COVID-19 pandemic has affected the lives and livelihood of American families. At … Read More
